Possible role of peritoneal NF-κB in peripheral inflammation and cancer: Lessons from the inhibitor DHMEQ

Biomedicine and Pharmacotherapy

Volumn 65, Issue 4, 2011, Pages 252-259

  Umezawa, K ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

DHMEQ; NF B; Peritoneal cavity

Indexed keywords

ANTIINFLAMMATORY AGENT; APOLIPOPROTEIN; B RAF KINASE; BORTEZOMIB; CD24 ANTIGEN; CD44V ANTIGEN; CELL SURFACE RECEPTOR; CYSTEINE; DEHYDROXYMETHYLEPOXYQUINOMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; HISTAMINE; HISTAMINE DECARBOXYLASE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LATENT MEMBRANE PROTEIN 1; OSTEOCLAST DIFFERENTIATION FACTOR; PANEPOXYDONE; PARIETAL CELL ANTIBODY; PHYTOHEMAGGLUTININ; TAX PROTEIN; THY 1 ANTIGEN; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFAT C1; TRANSCRIPTION FACTOR REL; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ATHEROSCLEROSIS; ATOPIC DERMATITIS; B CELL LYMPHOMA; BLADDER CANCER; BONE ATROPHY; BONE MARROW CELL; BREAST CANCER; BREAST CARCINOMA; CACHEXIA; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOKINE PRODUCTION; DRUG DNA BINDING; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; EPSTEIN BARR VIRUS; GENE MUTATION; GLOMERULONEPHRITIS; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HODGKIN DISEASE; HUMAN; HUMAN HERPESVIRUS 8; HUMAN T CELL LEUKEMIA VIRUS 1; IMMUNOHISTOLOGY; INFLAMMATION; INFLAMMATORY CELL; KIDNEY INJURY; LD 50; LEUKOCYTOSIS; LYMPHOBLASTOID CELL; METASTASIS; MIXED LYMPHOCYTE REACTION; MULTIPLE MYELOMA; NEOPLASM; NONHUMAN; OSTEOCLAST; PANCREAS CARCINOMA; PERITONEAL CAVITY; PERITONEUM CELL; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; RHEUMATOID ARTHRITIS; SPLEEN CELL; T CELL LEUKEMIA; TH1 CELL; THYROID CARCINOMA; UVEORETINITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; BENZAMIDES; CELL LINE, TUMOR; CYCLOHEXANONES; HUMANS; INFLAMMATION; MOLECULAR STRUCTURE; NEOPLASMS; NF-KAPPA B; PERITONEUM;

EID: 79960390177     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2011.02.003     Document Type: Review

References (55)

1. Sören B., Sten C. Functions of NF-κB1 and NF-κB2 in immune cell biology. Biochem J 2004, 382:393-409.
2. Li Q., Verma I.M. NF-κB regulation in the immune system. Nat Rev Immunol 2002, 2:331-367.
3. Kataoka T. Chemical biology of inflammatory cytokine signaling. J Antibiot (Tokyo) 2009, 62:655-667.
4. Kulms D., Schwarz T. NF-kappaB and cytokines. Vitam Horm 2006, 74:283-300.
5. Matsumoto N., Ariga A., To-e S., Nakamura H., Agata N., Hirano S., et al. Synthesis of NF-κB activation inhibitors derived from epoxyquinomicin C. Bioorg Med Chem Lett 2000, 10:865-869.
6. Erkel G., Anke T., Sterner O. Inhibition of NF-κB activation by panepoxydone. Biochem Biophys Res Commun 1996, 226:214-221.
7. Gehrt A., Erkel G., Anke T., Sterner O.A. Cycloepoxydon: 1-hydroxy-2-hydroxymethyl-3-pent-1-enylbenzene1-hydroxy-2-hydroxymethyl-3-pent-1, 3-dienylbenzene, new inhibitors of eukaryotic signal transduction. J Antibiot 1998, 51:455-463.
8. Suzuki Y., Sugiyama C., Ohno O., Umezawa K. Preparation and biological activities of optically active dehydroxymethylepoxyquinomicin, a novel NF-κB inhibitor. Tetrahedron 2004, 60:7061-7066.
9. Ariga A., Namekawa J., Matsumoto N., Inoue J., Umezawa K. Inhibition of TNF-α-induced nuclear translocation and activation of NF-κB by dehydroxymethyl-epoxyquinomicin. J Biol Chem 2002, 277:27625-27630.
10. Yamamoto M., Horie R., Takeiri M., Kozawa I., Umezawa K. Inactivation of nuclear factor kappa B components by covalent binding of (-)-dehydroxymethylepoxyquinomicin to specific cysteine residues. J Med Chem 2008, 51:5780-5788.
11. Kozawa I., Kato K., Teruya T., Suenaga K., Umezawa K. Unusual intramolecular N→O acyl group migration occurring during conjugation of (-)-DHMEQ with cysteine. Bioorg Med Chem Lett 2009, 19:5380-5382.
12. Suzuki E., Umezawa K. Inhibition of macrophage activation and phagocytosis by a novel NF-κB inhibitor, dehydroxymethylepoxyquinomicin. Biomed Pharmacother 2006, 60:578-586.
13. Suzuki E., Sugiyama C., Umezawa K. Inhibition of inflammatory mediator secretion by (-)-DHMEQ in mouse bone marrow-derived macrophages. Biomed Pharmacother 2009, 63:351-358.
14. Suzuki E., Ninomiya Y., Umezawa K. Induction of hisitidine decarboxylase in macrophages inhibited by the novel NF-kappa B inhibitor (-)-DHMEQ. Biochem Biophys Res Commun 2009, 379:379-383.
15. Takatsuna H., Asagiri M., Kubota T., Oka K., Osada T., Sugiyama C., et al. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-κB inhibitor, through downregulation of NFATc1. J Bone Mineral Res 2005, 20:653-661.
16. Asagiri M., Takayanagi H. The molecular understanding of osteoclast differentiation. Bone 2007, 40:251-264.
17. Kubota T., Hoshino M., Aoki K., Ohya K., Komano Y., Nanki T., et al. NF-κB inhibitor DHMEQ suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANCL OPG or M-CSF. Arthritis Res Ther 2007, 9:R97.
18. Wakamatsu K., Nanki T., Miyasaka N., Umezawa K., Kubota T. Effect of a small molecule inhibitor of nuclear factor-κB nuclear translocation in a murine model of arthritis and cultured human synovial cells. Arthritis Res Ther 2003, 7:1348-1359.
19. Miyajima A., Kosaka T., Seta K., Asano T., Umezawa K., Hayakawa M. Novel NF-κB activation inhibitor prevents inflammatory injury in unilateral urethral obstruction. J Urol 2003, 169:1559-1563.
20. Kosaka T., Miyajima A., Kikuchi E., Horiguchi Y., Umezawa K., Ohigashi T., et al. The novel NF-κB activation inhibitor dehydroxymethyl-epoxyquinomicin suppresses anti-Thy1.1-induced glomerulonephritis in rats. Nephron Exp Nephrol 2008, 110:e17-e24.
21. Kuroda K., Horiguchi Y., Nakashima J., Kikuchi E., Kanao K., Miyajima A., et al. Prevention of cancer cachexia by a novel nuclear factor κB inhibitor in prostate cancer. Clin Cancer Res 2005, 11:5590-5594.
22. Chiba T., Kondo Y., Shinozaki S., Kaneko E., Ishigami A., Maruyama N., et al. A selective NF-κB inhibitor, DHMEQ, reduced atherosclerosis in ApoE-deficient mice. J Atheroscler Thromb 2006, 13:308-313.
23. Suzuki T., Yamashita K., Jomen W., Ueki S., Aoyagi T., Fukai M., et al. The novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin, prevents local and remote organ injury following intestinal ischemia/reperfusion in rats. J Surg Res 2008, 149:69-75.
24. Nagai N., Oike Y., Izumi-Nagai K., Koto T., Satofuka S., Ozawa Y., et al. Suppression of diabetes-induced retinal inflammation by blocking angiotensin II type 1 receptor or its downstream NF-κB pathway. Invest Ophthalmol Vis Sci 2007, 48:4342-4350.
25. Iwata D., Kitaichi N., Ebihara A., Iwabuchi K., Yoshida K., Namba K., et al. Nuclear factor-κB inhibitor, dehydroxy methyl epoxyquinomicin ameliorates experimental autoimmune uveoreitnitis (EAU) in mice. Invest Ophthalmol Vis Sci 2010, 51:2077-2084.
26. Ueki S., Yamashita K., Aoyagi T., Haga S., Suzuki T., Itoh T., et al. Control of allograft rejection by applying a novel NF-κB inhibitor, dehydroxymethylepoxyquinomicin. Transplantation 2006, 82:1720-1727.
27. Nishioka C., Ikezoe T., Jing Y., Umezawa K., Yokoyama A. DHMEQ, a novel nuclear factor-kappaB inhibitor, induces selective depletion of alloreactive or phytohaemagglutinin-stimulated peripheral blood mononuclear cells, decreases production of T helper type 1 cytokines, and blocks maturation of dendritic cells. Immunology 2008, 124:198-205.
28. Hamasaka A., Yoshioka N., Abe R., Kishino S., Umezawa K., Ozaki M., et al. Topical application of DHMEQ improves allergic inflammation via NF-κB inhibition. J Allergy Clin Immunol 2010, 126:400-403.
29. Pikarsky E., Porat R.M., Stein I., Abramovitch R., Amit S., Kasem S., et al. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature 2004, 431:461-466.
30. Matsumoto G., Namekawa J., Muta M., Nakamura T., Bando H., Tohyama K., et al. Targeting of NF-κB pathways by DHMEQ, a novel inhibitor of breast carcinomas: Anti-tumor and anti-angiogenic activity in vivo. Clin Cancer Res 2005, 11:1287-1293.
31. Kikuchi E., Horiguchi Y., Nakashima J., Kuroda K., Oya M., Ohigashi T., et al. Suppression of hormone-refractory prostate cancer by a novel nuclear factor κB inhibitor in nude mice. Cancer Res 2003, 63:107-110.
32. Kodaira K., Kikuchi E., Kosugi M., Horiguchi Y., Matsumoto K., Kanai K., et al. Potent cytotoxic effect of a novel nuclear factor-kappa B inhibitor DHMEQ on human bladder cancer cells producing various cytokines. Urology 2010, 75:805-812.
33. Starenki D.V., Namba H., Saenko V.A., Ohtsuru A., Maeda S., Umezawa K., et al. Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, DHMEQ. Clin Cancer Res 2004, 10:6821-6829.
34. Palona I., Namba H., Mitsutake N., Starenki D., Podtcheko A., Sedliarou I., et al. BRAFV600E promotes invasiveness of thyroid cancer cells through NF-κB activation. Endocrinology 2006, 147:5699-5707.
35. Matsumoto G., Muta M., Umezawa K., dxSuzuki T., Mitsumi K., Tsuruta K., et al. Enhancement of the caspase-independent apoptotic sensitivity of pancreatic cancer cells by DHMEQ, an NF-κB inhibitor. Int J Oncol 2005, 27:1247-1255.
36. Watanabe M., Ohsugi T., Shoda M., Ishida T., Aizawa S., Maruyama-Nagai M., et al. Dual targeting of transformed and untransformed HTLV-1-infected T-cells by DHMEQ, a potent and selective inhibitor of NF-κB, as a strategy for chemoprevention and therapy of adult T cell leukemia. Blood 2005, 106:2462-2471.
37. Ohsugi T., Horie R., Kumasaka T., Ishida A., Ishida T., Yamaguchi K., et al. In vivo antitumor activity of the NF-κB inhibitor dehydroxymethyl-epoxyquinomicin in a mouse model of adult T-cell leukemia. Carcinogenesis 2005, 26:1382-1388.
38. Ohsugi T., Kumasaka T., Okada S., Ishida T., Yamaguchi K., Horie R., et al. Dehydroxymethylepoxyquinomicin (DHMEQ) therapy reduces tumor formation in mice inoculated with Tax-deficient adult T-cell leukemia-derived cell lines. Cancer Lett 2007, 257:206-215.
39. Watanabe M., Dewan M.Z., Okamura T., Sasaki M., Itoh K., Higashihara M., et al. A novel NF-κB inhibitor DHMEQ selectively targets constitutive NF-κB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo. Int J Cancer 2005, 114:32-38.
40. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2005, 5:417-421.
41. Tatetsu H., Okuno Y., Nakamura M., Matsuno F., Sonoki T., Taniguchi I., et al. A novel nuclear factor kappa B inhibitor induced apoptosis of multiple myeloma cells. Mol Cancer Ther 2005, 4:1114-1120.
42. Watanabe M., Dewan M.Z., Taira M., Shoda M., Honda M., Sata T., et al. IκBα independent induction of NF-κB and its inhibition by DHMEQ in Hodgkin/Reed-Sternberg cells. Lab Invest 2007, 87:372-382.
43. Luftig M., Yasui T., Soni V., Kang M.S., Jacobson N., Cahir-McFarland E., et al. Epstein-Barr virus latent infection membrane protein 1 TRAF-binding site induces NIK/IKK alpha-dependent noncanonical NF-kappaB activation. Proc Natl Acad Sci U S A 2004, 6:141-146.
44. Miyake A., Dewan Z., Ishida T., Watanabe M., Honda M., Sata T., et al. Induction of apoptosis in Epstein-Barr virus-infected B-lymphocytes by the NF-κB inhibitor DHMEQ. Microbes Infect 2008, 10:748-756.
45. Dabaghmanesh N., Matsubara A., Miyake A., Nakano K., Ishida T., Katano H., et al. Transient inhibition of NF-κB by DHMEQ induces cell death of primary effusion lymphoma without HHV-8 reactivation. Cancer Sci 2009, 100:737-746.
46. Murohashi M., Hinohara K., Kuroda M., Isagawa T., Tsuji S., Kobayashi S., et al. Gene set enrichment analysis provides insight into novel signaling pathways in breast cancer stem cells. Br J Cancer 2010, 102:206-212.
47. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2003, 420:860-867.
48. Umezawa K. Inhibition of tumor growth by NF-κB inhibitors. Cancer Sci 2006, 97:990-995.
49. Watanabe E., Mochizuki N., Ajima H., Ohno K., Shiino M., Umezawa K., et al. A simple and reliable method for determining plasma concentration of dehydroxymethylepoxyquinomicin by high performance liquid chromatography with mass spectrometry. J. Chromatogr B 2008, 871:32-36.
50. Shimada C., Ninomiya Y., Suzuki E., Umezawa K. Efficient cellular uptake of the novel NF-κB inhibitor (-)-DHMEQ and irreversible inhibition of NF-κB in neoplastic cells. Oncol Res 2010, 18:529-535.
51. Saitoh T., Suzuki E., Takasugi A., Obata R., Ishikawa Y., Umezawa K., et al. Efficient synthesis of (±)-parasitenone, a novel inhibitor of NF-(B. Bioorg Med Chem Lett 2009, 19:5383-5386.
52. Park B.K., Zhang H., Zeng Q., Dai J., Keller E.T., Giordano T., et al. NF-κB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nature Med 2007, 13:62-69.
53. Zins K., Abraham D., Sioud M., Aharinejad S. Colon cancer cell-derived tumor necrosis factor-α mediates the tumor growth-promoting response in macrophages by up-regulating the colony-stimulating factor-1 pathway. Cancer Res 2007, 67:1038-1045.
54. Vernon-Roberts B. Lymphocyte to macrophage transformation in the peritoneal cavity preceding the mobilization of peritoneal macrophages to inflamed areas. Nature 1969, 222:1286-1288.
55. Moro K., Yamada T., Tanabe M., Takeuchi T., Ikawa T., Kawamoto H., et al. Innate production of TH2 cytokines by adipose tissue-associated c-Kit+ Sca-1+ lymphoid cells. Nature 2010, 463:540-544.